An elderly woman with a recent history of MI is seeking a medication to help her occasional heartburn. She currently takes ASA, Clopidogrel, Simvastatin, Metoprolol and Lisinopril. Which of the following choices should be AVOIDED in this patient?

A. Calcium citrate: Calcium citrate is an antacid and calcium supplement that does not interact significantly with the patient’s current medications, including clopidogrel. It can be safely used to relieve occasional heartburn and support bone health in elderly patients without affecting platelet inhibition or cardiovascular risk. B. Famotidine: Famotidine is an H2 receptor antagonist that reduces gastric acid secretion. It does not inhibit CYP2C19 and therefore does not interfere with clopidogrel’s activation. Famotidine is generally safe for use in elderly patients with cardiovascular disease and concurrent antiplatelet therapy for management of occasional heartburn. C. Omeprazole: Omeprazole is a proton pump inhibitor (PPI) that is metabolized by CYP2C19. It can significantly reduce the conversion of clopidogrel into its active form, decreasing its antiplatelet effect. In a patient with a recent myocardial infarction, this interaction increases the risk of thrombotic events, making omeprazole the medication to avoid. D. Ranitidine: Ranitidine, also an H2 receptor antagonist, has minimal CYP2C19 inhibition and does not significantly interfere with clopidogrel metabolism. Although ranitidine has been withdrawn from many markets due to NDMA contamination concerns, from a drug interaction perspective it would not pose a major risk in this patient for clopidogrel efficacy. E. Calcium carbonate: Calcium carbonate acts as an antacid and does not interact with clopidogrel, aspirin, statins, or antihypertensives. It may provide temporary relief of heartburn symptoms. Patients should be advised to take it separately from other medications to avoid interference with absorption, but it is safe for use in this context.